(Q39404871)

11 September 2017

title

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia (English)

1 reference

11 September 2017

main subject

chronic myeloid leukemia

0 references

1 reference

7

1 reference

11 September 2017

Oliver Hantschel

1

0 references

Florian Grebien

object named as

Florian Grebien

5

0 references

author name string

Wolfgang Warsch

2

1 reference

11 September 2017

Eva Eckelhart

3

1 reference

11 September 2017

Ines Kaupe

4

1 reference

11 September 2017

Kay-Uwe Wagner

6

1 reference

11 September 2017

Veronika Sexl

8

1 reference

11 September 2017

publication date

29 January 2012

1 reference

11 September 2017

published in

Nature Chemical Biology

1 reference

11 September 2017

volume

8

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

285-293

1 reference

The BCR-ABL story: bench to bedside and back

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Translation of the Philadelphia chromosome into therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Jak2: normal function and role in hematopoietic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Genetic complexity of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Hematopoietic cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Phosphotyrosine Signaling: Evolving a New Cellular Communication System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

Charting the molecular network of the drug target Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.775

The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22286129

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22286129

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22286129

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NCHEMBIO.775

1 reference

11 September 2017

1 reference